0000899243-16-028189.txt : 20160829 0000899243-16-028189.hdr.sgml : 20160829 20160829163122 ACCESSION NUMBER: 0000899243-16-028189 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160825 FILED AS OF DATE: 20160829 DATE AS OF CHANGE: 20160829 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hooks Corwin Dale CENTRAL INDEX KEY: 0001665347 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 161858176 MAIL ADDRESS: STREET 1: C/O CLOVIS ONCOLOGY, INC. STREET 2: 5500 FLATIRON PARKWAY CITY: BOULDER STATE: CO ZIP: 80301 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-08-25 0 0001466301 Clovis Oncology, Inc. CLVS 0001665347 Hooks Corwin Dale C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY BOULDER CO 80301 0 1 0 0 See Remarks Stock Option (right to buy) 22.73 2016-08-25 4 A 0 27800 0.00 A 2026-08-25 Common Stock 27800 27800 D Restricted Stock Units 2016-08-25 4 A 0 13900 0.00 A Common Stock 13900 13900 D Stock Option (right to buy) 20.90 2026-02-01 Common Stock 10000 10000 D Stock Option (right to buy) 19.37 2026-03-01 Common Stock 10000 10000 D The option shall vest as to 25% of the shares on August 25, 2017, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. Each restricted stock unit represents the right to receive one share of Common Stock. The restricted stock units shall vest as to 25% of the units on August 25, 2017, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date. The option shall vest as to 25% of the shares on February 1, 2017, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. The vesting schedule for this option was incorrectly reported on a previously filed Form 4. This Form 4 reflects the correct vesting schedule. The option shall vest as to 25% of the shares on March 1, 2017, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. Senior Vice President and Chief Commercial Officer /s/ Corwin Dale Hooks 2016-08-29